Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Lab-on-a-Chip and Microfluidics Asia 2023

Valérie Taly's Biography



Valérie Taly, CNRS Research Director, Professor and Group leader Translational Research and Microfluidics, Université Paris Cité

V. Taly is a CNRS research director and group leader of the Translational Research And Microfluidics team within the clinical oncology research unit MEPPOT (personalized medicine pharmacogenomics and therapeutic optimization) in the Cordeliers Research Center (university Paris Cité). Her team performs interdisciplinary researches aiming at developing and validating microfluidic tools for cancer research in close collaboration with clinicians and researchers in oncology and toxicology. Since 2008, she developed droplet-based digital procedures for Cancer diagnosis. Recently, her research has been dedicated to the clinical validation of droplet-based microfluidics for the non-invasive detection of Cancer biomarkers, the highlighting of new Cancer Biomarkers and the development of original tools and procedures for their detection with applications in personalized medicine, cancer recurrence detection and cancer diagnostics. She is co-founder of EMULSEO (2018) and METHYS DX (2021) start up companies.

Valérie Taly Image

Droplet-Based Microfluidics to Detect Cancer Circulating Biomarkers: From Technology Development to Clinical Validation

Thursday, 5 October 2023 at 14:30

Add to Calendar ▼2023-10-05 14:30:002023-10-05 15:30:00Europe/LondonDroplet-Based Microfluidics to Detect Cancer Circulating Biomarkers: From Technology Development to Clinical ValidationLab-on-a-Chip and Microfluidics Asia 2023 in Tokyo, JapanTokyo, JapanSELECTBIOenquiries@selectbiosciences.com

Droplet-based microfluidics has led to the development of highly powerful tools with great potential in High-Throughput Screening where individual assays are compartmentalized within aqueous droplets acting as independent microreactors. Thanks to the combination of a decrease of assay volume and an increase of throughput, this technology goes beyond the capacities of conventional screening systems. Added to the flexibility and versatility of platform designs, such progresses in the manipulation of sub-nanoliter droplets has allowed to dramatically increase experimental level of control and precision. The presentation will aim at demonstrating through selected example, the great potential of this technology for biotechnology and cancer research. First, we will show how by combining microfluidic systems and clinical advances in molecular diagnostic we have developed an original method to perform millions of single molecule PCR in parallel to detect and quantify a minority of target sequences in complex mixture of DNA with a sensitivity unreachable by conventional procedures. Technological development allowing for the multiplex detection of cancer biomarkers will be presented. The presentation will also illustrate the pertinence of the developed procedures to overcome clinical oncology challenges, the results of several clinical studies will be presented. In particular, applications of droplet-based digital PCR to the follow-up of both advanced and localized cancers will be presented.


Add to Calendar ▼2023-10-05 00:00:002023-10-06 00:00:00Europe/LondonLab-on-a-Chip and Microfluidics Asia 2023Lab-on-a-Chip and Microfluidics Asia 2023 in Tokyo, JapanTokyo, JapanSELECTBIOenquiries@selectbiosciences.com